Therapeutic applications of trans-splicing

Abstract

Background: RNA trans-splicing joins exons from different pre-mRNA transcripts to generate a chimeric product. Trans-splicing can also occur at the protein level, with split inteins mediating the ligation of separate gene products to generate a mature protein.

Sources of data: Comprehensive literature search of published research papers and reviews using Pubmed.

Areas of agreement: Trans-splicing techniques have been used to target a wide range of diseases in both in vitro and in vivo models, resulting in RNA, protein and functional correction.

Areas of controversy: Off-target effects can lead to therapeutically undesirable consequences. In vivo efficacy is typically low, and delivery issues remain a challenge.

Growing points: Trans-splicing provides a promising avenue for developing novel therapeutic approaches. However, much more research needs to be done before developing towards preclinical studies.

Areas timely for developing research: Increasing trans-splicing efficacy and specificity by rational design, screening and competitive inhibition of endogenous cis-splicing.

Keywords: trans-splicing; cancer; gene therapy; genetic disease; infectious disease; ribozyme-mediated trans-splicing; spliceosome-mediated RNA trans-splicing (SMaRT); split intein-mediated trans-splicing.